DOCOMO, Japan's Largest Mobile Operator, to Unveil 31 Innovative Technologies—Some World Firsts—at docomo Open House'24
NTT DOCOMO, INC. announced today that it will unveil a number of world-first technologies among a total of 31 innovative technologies for 5G Evolution, 6G, Generative AI and more during docomo Open House'24, an exhibition of cutting-edge technological advancements to be held in Tokyo on January 17 and 18.
A dedicated website (https://docomo-openhouse24.smktg.jp/public/application/add/32) will be accessible from January 17 until February 29 to showcase the exhibits, including highlights such as the following.
5G Evolution & 6G
Sub-terahertz bandwidth for ultra-high-capacity communication over 100Gbps
Cutting-edge technologies such as extreme-high-speed transmissions over 100Gbps, together with AI, will be deployed to meet the advanced requirements of 6G in the coming future. As one example, DOCOMO will launch new communication infrastructure to harness sub-terahertz bandwidths for the integration of physical space and cyberspace.
https://docomo-openhouse24.smktg.jp/public/session/view/97
FEEL TECH® for sharing sensory perceptions via human-augmentation platform
FEEL TECH® is the world's first technology for sharing taste sensations between individuals via DOCOMO's human-augmentation mobile platform. It is expected to be used in the metaverse, as well as in movies and animations, to incorporate taste expressions into extra-rich content that people will experience with an immersive sense of presence.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1221_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/76
Network technology for non-terrestrial areas, including air, sea and space
In the future, networks incorporating high-altitude platform stations (HAPS) will support disaster communications, ship and drone connectivity, and communications in mountainous and remote areas. The exhibit will showcase the latest technologies for non-terrestrial network (NTN) HAPS and underwater drones for mobile coverage beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
https://www.docomo.ne.jp/english/info/media_center/pr/2023/1207_00.html
https://docomo-openhouse24.smktg.jp/public/session/view/101
Next-generation cloud slicing and 5GC on AWS to meet specific network needs
Tailoring networks to meet specific quality-of-service requirements remains a challenge. This innovative solution combines end-to-end orchestration, QoS visualization and monitoring, and 5G Core from AWS to deliver flexible network quality for specific locations and time scenarios. By integrating the cloud, energy efficiency and on-demand network quality, the solution will help realize highly sustainable networks.
https://docomo-openhouse24.smktg.jp/public/session/view/69
5G application to address diverse mobile needs in industrial settings
The adoption of 5G in the industrial sector is still limited. More extensive 5G implementation in the industrial world will require comprehensive analysis and multi-dimensional verification that can address diverse mobile needs and environments. DOCOMO has developed an advanced yet portable simulator that makes it easy to visualize 5G wireless transmission characteristics and electromagnetic interference effects in each customer's unique industrial setting.
https://docomo-openhouse24.smktg.jp/public/session/view/107
Generative AI
Enlivening the metaverse with generative AI that creates non-player characters
The world-first technology from DOCOMO uses generative AI to create non-player characters in the metaverse. The innovative technology, which automatically generates each character's appearance, behavior and role to eliminate the need for experts with specialized know-how, will help realize more enriched metaverse experiences in the future.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_01.html
https://docomo-openhouse24.smktg.jp/public/session/view/67
DOCOMO will also showcase a selection of the above technologies at MWC Barcelona 2024 from February 26to 29.
https://www.docomo.ne.jp/english/info/media_center/pr/2024/0116_00.html
Permission granted for the use of copyrighted images.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116271722/en/
Contact information
For further information, please contact:
NTT DOCOMO
Brand Communication Department
global_pr@nttdocomo.com
Weber Shandwick for NTT DOCOMO
nttdocomo@webershandwick.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom